#United States #Orlando #UCB #GMG #ZILBRYSQ

Exploring UCB's Latest Innovations in Generalized Myasthenia Gravis Treatment

At the 2026 AANEM (American Association of Neuromuscular Electrodiagnostic Medicine) Annual Meeting and the MGFA (Myasthenia Gravis Foundation of America) Scientific Session held from September 29 to October 2 in Orlando, Florida, UCB has reaffirmed its position as a leader in the treatment of generalized myasthenia gravis (gMG). The company presented comprehensive analyses and new data that showcase its innovative myasthenia gravis portfolio, including the efficacy and safety of ZILBRYSQ® (zilucoplan) and RYSTIGGO® (rozanolixizumab).

Key Findings and Presentations

Achievement of Minimal Symptom Expression

One of the pivotal discussions at the conference centered on achieving minimal symptom expression (MSE) among patients. Data from a 120-week post hoc analysis showed that patients receiving zilucoplan demonstrated significant improvements, with double-blind baseline Myasthenia Gravis Activities of Daily Living (MG-ADL) scores indicating positive outcomes. Similarly, findings from the Phase 3 trials of rozanolixizumab revealed meaningful milestones in symptom achievement.

Living with Ocular Myasthenia Gravis

Research highlighting the significant impact of ocular myasthenia gravis on patient quality of life was also presented. The study showed that patients experience a multifaceted burden that affects not only their daily functionality but also their emotional wellbeing and independence. The findings call for greater emphasis on providing multidisciplinary care and improved access to specialized services for patients with ocular symptoms.

Addressing Socioeconomic Disparities

UCB's research revealed a stark reality for Black patients with gMG, where traditional socioeconomic indicators fail to capture the unique risks they face. Utilizing the CORE-5 social risk screening tool, the research identified pressing unmet needs in areas such as housing and safety, underscoring the necessity for tailored care that acknowledges and addresses these social determinants.

Investigational Treatment: Cizutamig

Furthermore, early data regarding cizutamig, an investigational BCMA×CD3 T-cell engager, was shared, presenting promising avenues for future treatment. Cizutamig aims to reduce autoantibodies by targeting B cells and plasma cells, aiming to improve outcomes for gMG patients while minimizing potential adverse effects like cytokine release syndrome.

Insights from Experts

James F. Howard Jr., a prominent professor of neurology, emphasized the importance of measuring MSE over time to understand comprehensive disease control for patients. His insights highlight the need for continuous evaluation of patient treatment journeys to better inform clinical practices.

Donatello Crocetta, UCB’s Global Head of Medical Affairs, echoed the significance of incorporating diverse patient experiences into treatment considerations, noting that understanding unique challenges faced within the MG community is pivotal for enhancing research and care strategies.

Conclusion

UCB's participation in AANEM 2026 reflected its ongoing commitment to advancing the understanding and treatment of generalized myasthenia gravis. By bridging clinical insights, patient-reported outcomes, and innovative research, UCB continues to pave the way for enhanced patient-centered care in gMG treatment. This focus on targeted therapies not only addresses symptom relief but also the broader aspects of patient wellbeing and access to resources that can significantly impact living with this chronic condition.